PMV Pharmaceuticals closed at $1.32 on Nov 4, down 3.99%, 26.4% below its 52-week closing high. Volume of 530.4K shares was 1.18× its 20-day average (close to normal).
Split-adjusted performance: -17.7% over one month, -8.6% over six months, -5.4% over one year.
Short interest was 2.3M shares at the Oct 15 settlement, down 18.2% from the prior report (5.2% of float, 2.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PMVPPMV Pharmaceuticals | $1.33 | −3.99% | −8.6% | — | — | — | $70.8M | |
| MAIAMAIA Biotechnology | $1.14 | +5.56% | −15.6% | — | — | — | $70.4M | Compare |
| MNOVMedicinova | $1.45 | +2.11% | 0.0% | +240.6% | −504.8% | — | $71.4M | Compare |
| COYACoya Therapeutics | $3.08 | −0.96% | −27.4% | +49.0% | −2723.4% | — | $72.3M | Compare |
| CRBPCorbus Pharmaceuticals Holdings | $3.57 | −7.75% | −67.3% | — | — | — | $69.0M | Compare |
| TENXTenax Therapeutics | $1.81 | −1.63% | −84.9% | — | — | — | $67.7M | Compare |
| ACRVAcrivon Therapeutics | $1.74 | +4.19% | −16.7% | — | — | — | $74.6M | Compare |
| LFVNLifevantage Corporation Common Stock (Delaware) | $5.97 | +3.65% | −0.5% | −23.1% | 3.0% | 14.8 | $75.2M | Compare |
| CPIXCumberland Pharmaceuticals | $4.44 | +3.02% | +1.6% | −56.3% | −2569.0% | — | $66.5M | Compare |
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
